SLC1A5 and neoplasm: Various SLCs can transport glutamine, but specifically, ASCT2 (SLC1A5) has gained interest as a target for inhibiting glutamine uptake, given its general overexpression in tumor tissue and its use as a prognostic biomarker [21].